糖尿病前期市場－全球產業規模、佔有率、趨勢、機會和預測（按藥物類別、年齡層、地區和競爭細分，2020-2030 年）

2024 年全球糖尿病前期市場價值為 3.2451 億美元，預計到 2030 年將達到 6.0846 億美元，複合年成長率為 11.02%。隨著醫療保健系統越來越重視早期介入策略來應對日益加重的慢性代謝疾病負擔，全球糖尿病前期市場正受到越來越多的關注。糖尿病前期的特徵是血糖值升高，但尚未達到糖尿病診斷的程度，由於其與第 2 型糖尿病和心血管風險密切相關，因此受到越來越多的關注。隨著人們對早期發現和介入的認知不斷提高，篩檢和診斷評估的數量明顯增加，尤其是在高風險族群中。這推動了糖尿病前期患者的口服抗高血糖藥物、營養補充劑和生活方式管理計劃的需求。在公共衛生機構和私人利益相關者的合作支持下，預防性醫療保健融入標準臨床實踐正在加強市場基礎。

人們對主動疾病管理重要性的認知不斷提高，以及血糖監測和生活方式追蹤創新工具的可用性是關鍵的成長動力。穿戴式健康設備、行動健康應用程式和持續血糖監測系統使患者和提供者能夠即時追蹤健康指標，從而實現更個人化的治療方法。預測診斷領域的技術創新，包括使用生物標記和人工智慧風險評估工具，也在塑造糖尿病前期護理的未來。這些進步促進了有針對性的治療和數位健康平台的發展，這些治療和平台不僅支持血糖控制，而且還促進整體代謝健康。市場參與者透過擴大產品組合和建立旨在整合製藥、營養和行為解決方案的策略合作夥伴關係來應對。

關鍵市場促進因素

生活方式相關危險因子的盛行率不斷上升

主要市場挑戰

缺乏認知和診斷不足

主要市場趨勢

數位治療 (DTx) 與行動健康平台的融合日益加深

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球糖尿病前期市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依藥物類別（雙胍類、噻唑烷二酮類、胰高血糖素樣胜肽-1 激動劑 (GLP-1)、SGLT2 抑制劑、DPP-4 抑制劑、其他）
  • 依年齡層（兒童（12-18歲）、成人（18-49歲）、老年人（50歲以上））
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美糖尿病前期市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲糖尿病前期市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太糖尿病前期市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲糖尿病前期市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲糖尿病前期市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca
• Bristol-Myers Squibb Company
• Pfizer Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

Global Prediabetes Market was valued at USD 324.51 Million in 2024 and is expected to reach USD 608.46 Million in the forecast period with a CAGR of 11.02% through 2030. The Global Prediabetes Market is gaining traction as healthcare systems increasingly prioritize early intervention strategies to manage the growing burden of chronic metabolic conditions. Prediabetes, characterized by elevated blood glucose levels that are not yet high enough for a diabetes diagnosis, is receiving increased attention due to its strong correlation with type 2 diabetes and cardiovascular risks. As awareness around early detection and intervention grows, there is a noticeable rise in screenings and diagnostic assessments, particularly among high-risk populations. This is driving demand for oral antihyperglycemic agents, nutritional supplements, and lifestyle management programs tailored to prediabetic individuals. The integration of preventive healthcare into standard clinical practice, supported by collaborations between public health agencies and private stakeholders, is strengthening the market's foundation.

Growing awareness about the importance of proactive disease management and the availability of innovative tools for blood glucose monitoring and lifestyle tracking are key growth drivers. Wearable health devices, mobile health apps, and continuous glucose monitoring systems are enabling patients and providers to track health metrics in real-time, leading to more personalized treatment approaches. Technological innovation in predictive diagnostics, including the use of biomarkers and AI-powered risk assessment tools, is also shaping the future of prediabetes care. These advancements are encouraging the development of targeted therapies and digital health platforms that not only support glycemic control but also promote holistic metabolic wellness. Market players are responding by expanding product portfolios and entering strategic partnerships aimed at integrating pharmaceutical, nutritional, and behavioral solutions.

Key Market Drivers

Increasing Prevalence of Lifestyle-Related Risk Factors

The Global Prediabetes Market is experiencing significant growth, primarily driven by the escalating prevalence of lifestyle-related risk factors that contribute to the increasing number of individuals at risk of developing type 2 diabetes. Unhealthy dietary habits, physical inactivity, rising obesity rates, and high stress levels have become widespread, particularly in urban areas where sedentary jobs and the consumption of processed foods are prevalent. These behaviors lead to metabolic imbalances, insulin resistance, and elevated blood glucose levels, making individuals more susceptible to prediabetes. The rapid pace of urbanization and modernization has altered traditional lifestyles, encouraging habits that negatively impact glucose metabolism and weight management. Notably, younger age groups are increasingly being diagnosed with prediabetic conditions due to early exposure to processed foods, sugary beverages, irregular sleep cycles, and limited physical activity.

Recent statistics underscore the severity of these trends. According to the National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), more than one in three American adults have prediabetes. Furthermore, data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reveals that over 42.4% of U.S. adults have obesity, a significant increase over the past few decades. Physical inactivity also remains a critical concern, with only 25% of adults meeting the recommended physical activity guidelines. These factors collectively contribute to the rising incidence of prediabetes, emphasizing the urgent need for effective preventive measures.

Key Market Challenges

Lack of Awareness and Underdiagnosis

One of the most pressing challenges facing the Global Prediabetes Market is the persistent lack of awareness and widespread underdiagnosis, which significantly hampers early intervention and disease management efforts. Prediabetes is often asymptomatic, and many individuals remain unaware of their condition until it progresses to type 2 diabetes or leads to serious complications. This silent progression is a major concern, particularly in low- and middle-income countries where access to routine health checkups and diagnostic services is limited. Even in developed regions, public knowledge about prediabetes and its long-term risks remains inadequate, leading to delayed testing and missed opportunities for preventive care. Many people associate diabetes with advanced stages only, overlooking the critical window for intervention during the prediabetic phase.

Healthcare systems also contribute to the underdiagnosis due to a lack of standardized screening protocols and inconsistent application of risk assessment guidelines among general practitioners. In many clinical settings, blood glucose testing is not routinely performed unless the patient is already displaying obvious symptoms or has known risk factors. This reactive rather than proactive approach to disease identification leads to millions of individuals living with prediabetes without proper management. The absence of public health campaigns on par with those for cardiovascular or infectious diseases means prediabetes does not receive the attention it urgently requires. This gap delays diagnosis and increases the likelihood of long-term complications, raising the burden on healthcare infrastructures. To overcome this challenge, coordinated efforts involving policymakers, healthcare providers, and community outreach programs are essential to raise awareness, promote routine screenings, and ensure early identification of those at risk. Addressing this issue is vital not only to reduce the transition to diabetes but also to unlock the full potential of the growing market for diagnostics, therapeutics, and lifestyle management solutions targeted at prediabetic individuals.

Key Market Trends

Rising Integration of Digital Therapeutics (DTx) and Mobile Health Platforms

The rising integration of digital therapeutics (DTx) and mobile health platforms is significantly transforming the landscape of the Global Prediabetes Market. As healthcare systems shift toward preventive and personalized care, digital tools are emerging as powerful solutions for managing chronic metabolic conditions like prediabetes. Digital therapeutics are evidence-based software applications that deliver structured interventions to modify patient behavior, monitor glycemic trends, and support lifestyle changes. These platforms enable users to track physical activity, nutrition, sleep, and stress key factors in preventing the progression of prediabetes to type 2 diabetes. Many of these tools integrate seamlessly with wearable devices and continuous glucose monitors, offering real-time feedback and data-driven insights to both users and healthcare professionals. The convenience of remote access to coaching, educational content, and personalized plans has increased user engagement and compliance, especially among tech-savvy younger demographics and urban populations.

As smartphone penetration and internet access expand globally, mobile health platforms are becoming more accessible in both developed and emerging markets. These platforms not only improve patient outcomes but also reduce the burden on traditional healthcare infrastructure by decreasing the need for frequent in-person visits. Regulatory approvals and clinical validation of several digital therapeutics have enhanced trust among healthcare providers and payers, leading to greater adoption. Insurance companies and corporate wellness programs are beginning to reimburse or subsidize DTx tools, recognizing their cost-effectiveness in long-term disease management. As the demand for non-invasive, scalable, and personalized solutions grows, digital therapeutics and mobile platforms are poised to become essential components in early prediabetes intervention. This trend is expected to accelerate innovation, improve health literacy, and empower individuals to take greater control over their metabolic health through proactive engagement and preventive strategies. The integration of artificial intelligence and machine learning into these platforms is further enhancing predictive accuracy and personalized care pathways in prediabetes management.

Key Market Players

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca
• Bristol-Myers Squibb Company
• Pfizer Inc.

Report Scope:

In this report, the Global Prediabetes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prediabetes Market, By Drug Class:

• Biguanide
• Thiazolidinediones
• Glucagon-like peptide-1 agonists (GLP-1)
• SGLT2 inhibitors
• DPP-4 inhibitors
• Others

Prediabetes Market, By Age Group:

• Children (12-18 years)
• Adults (18-49)
• Elderly (50+)

Prediabetes Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prediabetes Market.

Available Customizations:

Global Prediabetes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Prediabetes Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Biguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others)
  • 5.2.2. By Age Group (Children (12-18 years), Adults (18-49), Elderly (50+))
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Prediabetes Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Age Group
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prediabetes Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Age Group
  • 6.3.2. Mexico Prediabetes Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Age Group
  • 6.3.3. Canada Prediabetes Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Age Group

7. Europe Prediabetes Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Age Group
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Prediabetes Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Age Group
  • 7.3.2. Germany Prediabetes Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Age Group
  • 7.3.3. United Kingdom Prediabetes Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Age Group
  • 7.3.4. Italy Prediabetes Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Age Group
  • 7.3.5. Spain Prediabetes Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Age Group

8. Asia-Pacific Prediabetes Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Age Group
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Prediabetes Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Age Group
  • 8.3.2. India Prediabetes Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Age Group
  • 8.3.3. South Korea Prediabetes Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Age Group
  • 8.3.4. Japan Prediabetes Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Age Group
  • 8.3.5. Australia Prediabetes Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Age Group

9. South America Prediabetes Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Age Group
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Prediabetes Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Age Group
  • 9.3.2. Argentina Prediabetes Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Age Group
  • 9.3.3. Colombia Prediabetes Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Age Group

10. Middle East and Africa Prediabetes Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Age Group
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Prediabetes Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Age Group
  • 10.3.2. Saudi Arabia Prediabetes Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Age Group
  • 10.3.3. UAE Prediabetes Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Age Group

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Novo Nordisk A/S
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Valbiotis
• 14.3. RESVERLOGIX
• 14.4. Caelus Health
• 14.5. Scimar
• 14.6. Boston Pharmaceuticals
• 14.7. APHAIA PHARMA AG
• 14.8. AstraZeneca
• 14.9. Bristol-Myers Squibb Company
• 14.10. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer